Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

Core Insights - Coherus BioSciences has initiated a Phase 1b/2 clinical study to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor, targeting various cancers including non-small cell lung cancer (NSCLC) and melanoma [1][2] Company Overview - Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes mid-stage candidates for liver, lung, and head & neck cancers [3] - The company aims to expand LOQTORZI's indications beyond nasopharyngeal carcinoma through strategic collaborations and cost-efficient drug supply agreements [2][3] Clinical Study Details - The Phase 1b/2 study will assess the safety and efficacy of the STC-15 and LOQTORZI combination, with up to 188 patients enrolled in the United States [2] - STORM Therapeutics is the sponsor of the trial, while Coherus will supply LOQTORZI, retaining commercial rights for both compounds [2] Immuno-Oncology Pipeline - Coherus' pipeline includes multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [4] - Notable candidates include Casdozokitug, an IL-27 antagonistic antibody, and CHS-114, a selective anti-CCR8 antibody, both in various stages of clinical trials [4]